JS-008(JS-008) - _专利_临床

概要

基本信息

药物类型

生物药

别名

靶点-

作用方式-

作用机制-

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

代谢性疾病

原研机构

上海君实生物医药科技股份有限公司

在研机构-

非在研机构

上海君实生物医药科技股份有限公司

最高研发阶段无进展临床前

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

关联

100 项与 JS-008 相关的临床结果

登录后查看更多信息

100 项与 JS-008 相关的转化医学

登录后查看更多信息

100 项与 JS-008 相关的专利（医药）

登录后查看更多信息

1

项与 JS-008 相关的文献（医药）

1986-07-01·Cell1区 · 生物学

Control of erythroid differentiation: Possible role of the transferrin cycle

1区 · 生物学

Article

作者: Prem Ponka ; Jerzy A. Schmidt ; Hartmut Beug ; Michael J. Hayman ; John Marshall

A monoclonal antibody to the chicken transferrin receptor (JS-8) blocked temperature-induced and spontaneous differentiation of avian erythroid cells transformed by ts- and wt-retroviral oncogenes. In cells committed to differentiate, JS-8 caused an arrest at the erythroblast or early reticulocyte stage, followed by premature cell death, whereas proliferation of noncommitted erythroid cells or other hematopoietic cells remained unaffected. JS-8 had no effect on transferrin binding or internalization, but blocked subsequent receptor-recycling resulting in reduced iron uptake. Restoration of high intracellular iron levels neutralized the action of JS-8, whereas an inhibitor of porphyrine biosynthesis (4,6-dioxoheptanoic acid) closely mimicked the effect of JS-8. This suggests that erythroid differentiation might involve coordinate synthesis of erythrocyte proteins subject to regulation by hemin or hemoglobin.

100 项与 JS-008 相关的药物交易

登录后查看更多信息